bioAffinity Technologies has announced that the U.S. Patent and Trademark Office issued a new patent for a novel cancer therapeutic. This patent covers a method for selectively killing cancer cells by targeting CD320 and LRP2 receptors on cell membranes using small interfering RNAs (siRNAs). The approach has shown promise in selectively targeting cancer cells without affecting normal cells, providing a potential new treatment path for various cancers including lung, breast, prostate, brain, and skin. bioAffinity Technologies is focusing its initial efforts on developing a topical treatment for skin cancer.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.